Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115

We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115. The primary objective was to evaluate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sanchorawala, V, Hoering, A, Seldin, DC, Finn, KT, Fennessey, SA, Sexton, R, Mattar, B, Safah, HF, Holmberg, LA, Dean, RM, Orlowski, RZ, Barlogie, B
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3855173/
https://ncbi.nlm.nih.gov/pubmed/23852321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2013.98
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados